Free Trial

Takeda Pharmaceutical (TAK) Competitors

Takeda Pharmaceutical logo
$15.55 +0.13 (+0.84%)
Closing price 03:32 PM Eastern
Extended Trading
$15.46 -0.09 (-0.57%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TAK vs. SNY, GSK, ARGX, ONC, BNTX, TEVA, SMMT, ITCI, GMAB, and RDY

Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

Takeda Pharmaceutical vs. Its Competitors

Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Sanofi pays an annual dividend of $1.59 per share and has a dividend yield of 3.3%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.5%. Sanofi pays out 56.8% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$45.17B2.65$6.02B$2.8017.46
Takeda Pharmaceutical$30.09B1.64$712.33M$0.2270.68

14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sanofi has a net margin of 14.56% compared to Takeda Pharmaceutical's net margin of 2.36%. Sanofi's return on equity of 17.15% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi14.56% 17.15% 9.80%
Takeda Pharmaceutical 2.36%10.64%5.14%

In the previous week, Sanofi had 19 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Sanofi and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.67 beat Sanofi's score of 0.65 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
6 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Takeda Pharmaceutical
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sanofi currently has a consensus target price of $61.50, suggesting a potential upside of 25.81%. Given Sanofi's stronger consensus rating and higher probable upside, equities analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.11
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Sanofi has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Summary

Sanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TAK vs. The Competition

MetricTakeda PharmaceuticalMED IndustryMedical SectorNYSE Exchange
Market Cap$49.48B$2.41B$5.48B$20.62B
Dividend Yield3.59%1.77%5.39%3.77%
P/E Ratio70.698.9827.4328.04
Price / Sales1.64468.84398.4736.83
Price / Cash4.83151.5836.1321.91
Price / Book1.084.638.084.59
Net Income$712.33M$31.34M$3.16B$985.44M
7 Day Performance3.08%0.84%2.12%2.91%
1 Month Performance3.87%7.92%4.43%5.47%
1 Year Performance18.66%1.87%35.62%14.61%

Takeda Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TAK
Takeda Pharmaceutical
1.4845 of 5 stars
$15.55
+0.8%
N/A+18.5%$49.48B$30.09B70.6949,281
SNY
Sanofi
4.3781 of 5 stars
$48.18
+0.7%
$61.50
+27.6%
+1.6%$118.16B$44.46B17.2182,878Analyst Forecast
GSK
GSK
2.1523 of 5 stars
$38.26
+0.5%
$37.38
-2.3%
+0.8%$78.33B$40.10B19.7268,629Options Volume
ARGX
argenex
4.3217 of 5 stars
$540.76
-0.3%
$709.18
+31.1%
+25.2%$33.02B$2.25B33.361,599Analyst Forecast
ONC
BeOne Medicines
3.5878 of 5 stars
$257.51
+4.2%
$319.00
+23.9%
N/A$28.22B$3.81B-69.2211,000
BNTX
BioNTech
2.5644 of 5 stars
$103.01
-3.3%
$137.86
+33.8%
+37.5%$24.76B$2.98B-30.306,772
TEVA
Teva Pharmaceutical Industries
4.2172 of 5 stars
$16.96
+0.1%
$24.44
+44.1%
+3.0%$19.45B$16.54B-14.7536,830
SMMT
Summit Therapeutics
2.6908 of 5 stars
$20.39
-0.8%
$35.09
+72.1%
+200.0%$15.14B$700K-59.97110Trending News
Analyst Forecast
Options Volume
Trading Halted
ITCI
Intra-Cellular Therapies
0.9954 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.596 of 5 stars
$20.68
-2.3%
$39.17
+89.4%
-17.9%$13.26B$3.12B11.752,682High Trading Volume
RDY
Dr. Reddy's Laboratories
2.8419 of 5 stars
$15.31
+0.5%
$16.95
+10.7%
-2.3%$12.78B$3.81B23.2027,811Positive News

Related Companies and Tools


This page (NYSE:TAK) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners